Highest-materiality recent filing
Horizon Space Acquisition II extends deadline to May 18, 2026 with $50K sponsor deposit
Sponsor deposited $50,000 into trust account for third one-month extension to May 18, 2026.
HSPT secures $7.8M PIPE commitment for SL Bio business combination
PubCo entered subscription agreements for 780,000 units at $10/unit, raising $7.8M.
Extension from March 18 to April 18, 2026 is the second of up to twelve monthly extensions permitted.
Horizon Space II extends deadline to March 18, 2026 with $50K deposit; over 6.7M shares redeemed
William Wang deposited $50,000 extension fee into trust for one-month extension to March 18, 2026; up to 12 monthly extensions available.
Shareholders approve SPAC merger with SL Bio and extension to Feb 2027
Business combination with SL Bio approved; 5,031,013 FOR, 1,166,644 AGAINST.
Horizon Space Acquisition II adds two independent director nominees for post-merger board
Joseph Levinson (CPA, 25+ yrs public company exp.) named independent director nominee of PubCo.
HSPT clarifies redemption process for Business Combination and Extension Meetings
Shareholders who previously elected redemption for the Business Combination Meeting must also instruct redemption for the Extension Meeting by 5:00 p.m. ET on Feb 11, 2026 to ensure redemption.
Extraordinary general meeting postponed from Feb 3 to Feb 12, 2026 at 9:00 a.m. ET.
HSPT corrects proxy statement to update trust agent and transfer agent contact info
Corrects trust agent reference to Wilmington Trust, National Association.
Horizon Space Acquisition II extends deadline to Feb 18, 2026 via $690k deposit and promissory note
Company extended initial business combination deadline by three months to February 18, 2026.
Horizon Space Acquisition II issues $300K promissory note to sponsor for working capital
Unsecured note of $300,000 issued to Horizon Space Acquisition II Sponsor Corp. on July 5, 2025.
Horizon Space Acquisition II SPAC to merge with SL Bio at $5.568B enterprise value
SL Bio develops cellular and gene therapies; will become wholly owned sub of PubCo via two-step merger.
Horizon Space Acquisition II announces separate trading of shares and rights starting Feb 5
Holders of 5,750,000 units may elect to separate ordinary shares and rights starting Feb 5, 2025.
SPAC Horizon Space II closes over-allotment option, raising $9M additional
Underwriters exercised over-allotment in full: 900,000 Units at $10.00/unit, gross proceeds $9,000,000.
Horizon Space Acquisition II completes $60M IPO; auditor flags going concern risk
Sold 6M units at $10 each, gross proceeds $60M; over-allotment later closed for extra 900K units ($9M).
Horizon Space Acquisition II Corp. closes $60M IPO; $62M placed in trust
Priced 6,000,000 units at $10.00/unit, gross proceeds $60M; units trade on Nasdaq under HSPTU.
Effective on November 12, 2024, in connection with the effectiveness of the Registration Statement, James Jiayuan Tong, Qian (Hebe) Xu, and Tianchen Cai became directors of the Company.
Effective on November 12, 2024, in connection with the effectiveness of the Registration Statement, James Jiayuan Tong, Qian (Hebe) Xu, and Tianchen Cai became directors of the Company.
Effective on November 12, 2024, in connection with the effectiveness of the Registration Statement, James Jiayuan Tong, Qian (Hebe) Xu, and Tianchen Cai became directors of the Company.
Max materiality 0.85 · Median 0.45 · Most common event other_material